Osteonecrosis after intranasal injection with bevacizumab in treating hereditary hemorrhagic telangiectasia: A case report
| Autor: | Else Merckoll, Sinan Dheyauldeen, Ketil Heimdal, John Magnar Slåstad, Johan Steineger, Erik Fink Eriksen |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
030203 arthritis & rheumatology
medicine.medical_specialty Bevacizumab business.industry Treatment outcome Mucous membrane of nose Surgery 03 medical and health sciences 0302 clinical medicine Otorhinolaryngology Anesthesia medicine Effective treatment Nasal administration In patient medicine.symptom 030223 otorhinolaryngology Adverse effect business Telangiectasia medicine.drug |
| Zdroj: | The Laryngoscope. 128:593-596 |
| ISSN: | 0023-852X |
| DOI: | 10.1002/lary.26722 |
| Popis: | Intranasal bevacizumab injections have been used in treating hereditary hemorrhagic telangiectasia (HHT)-related epistaxis since 2009. It is believed to be a safe and effective treatment for a selected group of HHT patients in reducing frequency and intensity of epistaxis, with few or none adverse effects. In this case report, however, we will describe a patient who developed bilateral osteonecrosis in the knees while undergoing regular intranasal submucosal bevacizumab injections. Although osteonecrosis previously has been documented in patients receiving bevacizumab intravenously in oncologic doses, thus far it has not been reported in patients treated with intranasal submucosal injections. Laryngoscope, 128:593-596, 2018. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text